Zura Bio (NASDAQ:ZURA – Free Report) had its target price decreased by HC Wainwright from $5.00 to $3.00 in a research report ...

Analysts at HC Wainwright issued their FY2028 earnings per share estimates for shares of Cytosorbents in a research note issued to investors on Thursday, April 3rd. HC Wainwright analyst S. Lee ...

H.C. Wainwright raised the firm’s price target on Compass Therapeutics (CMPX) to $24 from $10 and keeps a Buy rating on the shares. The company ...

Fintel reports that on April 2, 2025, HC Wainwright & Co. upgraded their outlook for Sarepta Therapeutics (NasdaqGS:SRPT) ...

H.C. Wainwright lowered the firm’s price target on I-Mab (IMAB) to $7 from $8 and keeps a Buy rating on the shares. The company continues to ...

Fintel reports that on April 3, 2025, HC Wainwright & Co. initiated coverage of Kairos Pharma (NYSEAM:KAPA) with a Buy ...

Sarepta and Roche paused Elevidys trials in the EU after a patient death. Analysts warn of potential sales declines as safety concerns impact market outlook.

On Friday, H.C. Wainwright’s analysts reaffirmed a Buy rating on Altimmune (NASDAQ:ALT) shares, with a steady price target of $12.00. According to InvestingPro data, the stock is currently ...

H.C. Wainwright says Novo Nordisk’s (NVO) REDEFINE-2 results reinforce Viking Therapeutics’ (VKTX) VK2735’s potential in obesity and beyond. Assuming full adherence, Novo’s CagriSema ...

On Thursday, H.C. Wainwright analyst Andrew Maldonado maintained a Buy rating and a $36.00 price target for Day One Biopharmaceuticals (NASDAQ:DAWN) shares, representing significant upside potential ...

Fintel reports that on April 3, 2025, HC Wainwright & Co. initiated coverage of Kairos Pharma (NYSEAM:KAPA) with a Buy recommendation. As of April 2, 2025, the average one-year price target for ...